Potential Biomarkers for Early Diagnosis of Acute Aortic Dissection
NCT ID: NCT01860768
Last Updated: 2013-05-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2013-05-31
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Parts small sample tests found that single serum α-smooth muscle actin (α-SMA), myosin heavy chain(MHC) and human soluble elastin fragments (sELAF) levels in patients with AAD were significantly higher than that of others (normal people, acute myocardial infarction patients). But because of the small study sample, limited control risk factors and incomplete comparison, their conclusions were questionable. In our previous studies also found that serum α-SMA, MHC and sELAF levels and the pathogenesis of AAD and prognosis are closely related. Therefore, on the basis, a prospective study is needed. We observe all the three biomarkers in enrolled patients with acute chest pain in emergency department, levels in healthy volunteers as the blank control. Then make definite diagnosis of the enrolled patients, and further observe the biomarkers dynamic change in AAD. Lastly, evaluate the early diagnostic value of combination serum α-SMA, MHC and sELAF level on patients with AAD.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Blood Biomarker Discovery by Raman Spectroscopy in Acute Aortic Dissection
NCT05206032
Quick Recognition of Aortic Dissection
NCT05699395
Aortic Dissection Detection Risk Score Plus D-dimer in Suspected Acute Aortic Dissection
NCT02086136
Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Multicenter Cohort Study) III
NCT04918108
Potential Diagnostic Biomarkers for Aortic Dissection in the Emergency Department
NCT06065306
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Subjects enrolled in this study will sign and informed consent and have 3 blood samples drawn at different time points during their emergency department visit. In addition, data will be collected about the patient's health history, hospital procedures, and final diagnosis.
Blood samples collected in this study will be sent to laboratory for long-term storage and analysis in the future for these blood markers as they become available. No genetic testing will be conducted on these samples.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
acute aortic dissectin patients
definite diagnosis by computed tomography arteriography (CTA).
No interventions assigned to this group
acute chest pain patients
aortic dissection is exclude by aorta CTA
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* symptom occurred in 2 hours
* ≥18 years old
* Can complete the base information
* Able and willing to give written consent
Exclusion Criteria
* known causes of acute chest pain such as tumour and trauma
* pregnant or lactating female
* Associated chronic inflammatory diseases
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central South University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
CHAI Xiangping
vice director of emergency department; vice director of hospital office
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2XY-ED-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.